Eric Archambeau
Board Of Directors @ Ynsect
London, United Kingdom
Eric Archambeau is a Senior Advisor at technology companies. Eric joined Wellington as a General Partner in early 2005 focusing on Digital Media, Software, Cleantech and Electronics.From 2000 to 2002, he was at Benchmark Capital where he lead and co-lead a number of deals including Betfair, Orchestria, Xignal and Activiti (now Alfresco), as well as pioneering an active Entrepreneur in Residence programme in London. Eric joined Benchmark from Atlas Venture where, in Silicon Valley, he worked with companies including Tsqware (acquired by Globespan) and Obongo (acquired by AOL).Before 1999, Eric was a serial entrepreneur. First in 1993, as co-founder and CEO of RightPoint, a provider of marketing automation enterprise software (acquired by e.piphany), then, in 1998, as founding CEO of Trading Dynamics (acquired by Ariba). Eric was also a founding board member of eGroups, acquired by Yahoo! in 2000. In the 1980s he worked in the semiconductor and EDA industry in Silicon Valley, most notably with VLSI Technology Inc.Eric is one of the founders of Social-Impact, a professional development programme helping social entrepreneurs worldwide to increase their social impact and reach their full potential. He also lectured at INSEAD where he founded the Social Entrepreneurship department.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Eric Archambeau invests in
Stages Eric Archambeau invests in
Countries Eric Archambeau invests in
Round sizes
Round size
- Seed
- $550k–$18M
- Series A
- $3.8M–$20M
- Series B
- $6M–$29M
Investment Focus
Industry
- Software 5 (18%)
- Apps 4 (14%)
- Music 4 (14%)
- E-Commerce 4 (14%)
- Biotechnology 4 (14%)
Stage
- Series A 11 (39%)
- Series B 7 (25%)
- Seed 3 (11%)
- Funding Round 3 (11%)
- Series C 1 (4%)
Country
- United States 7 (25%)
- United Kingdom 4 (14%)
- France 3 (11%)
- Sweden 3 (11%)
- Finland 2 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RFI Ingredients
|
RFI Ingredients is a formulation-driven company, that engages in providing exceptional products, solutions, and services for the dietary supplement, beverage, and food industries. | Venture - Series Unknown / Jul 28, 2026 | |
Omeza
|
Omeza is a hospital and healthcare company that provides wound care, venous leg ulcers, omega 3, and innovation. The company is driven by its mission is to improve healthcare efficiency one market at a time, beginning with wound care. The company was founded in 2014 and headquartered in Florida, United States. | $8.5M / Series A / Apr 21, 2026 | |
Standing Ovation
|
Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $28.6M / Series B / Mar 31, 2026 | |
Laced
|
Laced is a marketplace for the buying and selling of authentic sneakers, connecting thousands of buyers and sellers worldwide. | $12M / Series A / May 24, 2023 | |
|
Standing Ovation
|
Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $12M / Series A / Sep 14, 2022 | |
Current Foods
|
Kuleana creates plant-based alternatives for people's seafood favorites, using plants and biotechnology without the environmental and ethical consequences. | $18M / Seed / Jun 23, 2022 | |
SignalRank
|
SignalRank Corporation is a FinTech company in the Venture space. It focuses on the seed stage asset class and uses data analytics to allocate capital to the best seed fund managers for their top performing companies. GPRank and CompanyRank are two proprietary algorithms it leverages to automate capital allocation. The company invests from balancesheet. Its customers are seed stage investors with outstanding companies in their portfolio. | $5.1M / Seed / Nov 14, 2021 | |
Stockeld Dreamery
|
We set off with a first vision: to create a cheese that is superior in taste and nutrition, constantly striving to use our planet’s resources wisely, accessible to all yet one of the top preferred cheeses by chefs and restaurants. Simply put, the world’s most ambitious cheese. | $19.6M / Series A / Sep 02, 2021 | |
|
Stockeld Dreamery
|
We set off with a first vision: to create a cheese that is superior in taste and nutrition, constantly striving to use our planet’s resources wisely, accessible to all yet one of the top preferred cheeses by chefs and restaurants. Simply put, the world’s most ambitious cheese. | $19.6M / Series A / Sep 02, 2021 | |
Modern Meadow
|
Modern Meadow is developing fundamentally new approaches to growing animal products. This includes cultured leather and meat products that require no animal slaughter and much lower inputs of land, water, energy, and chemicals. | $130M / Series C / Apr 29, 2021 | |
| See all 28 investments → | |||
Co-Investors
About Ynsect
Ynsect provides products and services that operate in the agro-food and environmental biotech industries. It uses the potential of insect nutrients and behaviors to develop novel products and services in collaboration with their clients. Since 2011, Ÿnsect has been transforming farmed insects into premium animal nutrition. They are developinginnovations to farm insects at large scale and automating processes to turn insects into the highest quality raw materials for animal feed. Its unique know-how makes Ÿnsect a preferred partner among agri-food professionals, laboratories, investors, public institutions, and insect industry farmers.
Ynsect Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexis Angot
Co-Founder and Secretary General
|
|||
Jean-Gabriel Levon
Vice President
|
|||
Antoine Hubert
CEO & Chairman of the Board
|
|||
Benjamin Armenjon
Business Development Director
|
|||
|
Eric Archambeau
Board Of Directors
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eric Archambeau invest in?
Eric Archambeau invests primarily in Software, Apps and Music startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eric Archambeau's check size?
Eric Archambeau typically joins rounds of $550k–$18M at Seed, $3.8M–$20M at Series A and $6M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eric Archambeau participates in.
When did Eric Archambeau last invest?
The most recent investment recorded for Eric Archambeau closed in Jul 2026. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
